An international consortium of epidemilogists - including Dr. Alexandra Nieters and Professor Nikolaus Becker of the Clinical Epidemiology Division of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) - has conducted the first ever investigation of genetic factors in the development of non-Hodgkin’s lymphoma (NHL) in a study called InterLymph.
The researchers collaborating within the International Lymphoma Epidemiology Consortium have found out that variations of individual DNA building blocks in genes encoding for the cellular signaling molecules tumor necrosis factor (TNF) and interleukin 10 (IL-10) increase the risk of developing non-Hodgkin’s lymphoma.
The study is a step towards developing a deeper understanding of the development of lymphomas, which may lead to novel prevention and treatment approaches in the future. The researchers have now published their results online in the journal Lancet Oncology.
The study is based on data gathered in eight case-control studies from different countries involving a total of 3586 NHL patients and 4018 healthy individuals as control group. The epidemiologists focused their attention on 12 different variations of single DNA building blocks, called single nucleotide polymorphisms, which are located in genes whose products regulate important functions in immune response and anti-inflammatory reaction. For two variations concerning the genes for (i) tumor necrosis factor and (ii) interleukin, the investigators found an elevated individual risk of non-Hodgkin’s lymphoma. Analyzing different NHL subtypes, they discovered that the two gene variations specifically increase the risk of diffuse large B-cell lymphoma, the most common type of malignant lymphoma. The disease risk of individuals carrying one copy of the rare polymorphism in the TNF gene is elevated by 29 percent; a second copy increases the risk by 65 percent. A combination of both gene variants in TNF and IL-10 leads to a 100 percent increase of individual risk. The risk of follicular lymphoma, a generally less aggressive type of lymphoma, is not influenced by the combination of these variants.
In recent years, lymphoma research has focused primarily on the search for environmental or lifestyle risk factors. The study now published is an important step towards a deeper understanding also of genetic factors in NHL development. “We have had two hits in twelve factors we investigated. Now the real work starts, because we are planning to study not only the influence of genetic factors on the development of non-Hodgkin’s lymphomas, but also on lymphomas in general. Basically, we are interested here in all genes that influence signaling pathways within the cell such as in inflammatory processes or cellular DNA repair mechanisms,” states Alexandra Nieters, assessing the relevance of the study for lymphoma research. In the future, epidemiologists are planning to put more emphasis on combined investigations of genetic and environmental factors in lymphoma development.